pharmaceutical
originators
Microinnova provides end-to-end solutions for pharmaceutical originators to transition from batch to continuous manufacturing. We specialize in rapid process development, PAT-integrated flow chemistry, and modular plant design to ensure safe, scalable, and cost-efficient API synthesis.
Accelerating Time-to-Market for Pharmaceutical Originators
via Continuous Manufacturing & Flow Chemistry
Accelerated R&D and Scalability: Utilizing Design of Experiments (DoE) and Digital Twins to predict process behavior and reduce the time from lab-scale to full-scale production.
Enhanced Safety for Critical Reactions: Expert handling of hazardous or highly exothermic transformations (e.g., Fluorination, Nitration) through precise continuous flow control.
Real-time Quality Assurance: Integration of Process Analytical Technology (PAT) and Model Predictive Control (MPC) for automated, 24/7 quality monitoring and regulatory compliance.
Cost-Efficient Modular Design: Flexible, modular flow plant systems (FlowKiloLab®, FlowTonPlant) that allow for rapid reconfiguration and lower CAPEX.
Continuous Manufacturing for Pharma Originators: FAQs
How does continuous manufacturing benefit pharmaceutical originators?
Continuous manufacturing reduces footprint, minimizes human error, and allows for the production of molecules that are too unstable or dangerous for traditional batch reactors.
Â
Can batch processes be converted to continuous flow?
Yes. Microinnova uses a “batch-to-conti” methodology, analyzing kinetics and thermodynamics to re-engineer existing batch protocols into efficient continuous streams.
Â
What technologies are used in Microinnova’s flow plants?
Our systems integrate Digital Twins, PAT, and automated dosing to ensure maximum process stability and data integrity.
Your benefit.
Our solutions.
Microinnova delivers customized solutions to meet your industry’s unique challenges. With expertise in process development, continuous manufacturing, and modular plant design, we enhance efficiency, accelerate time-to-market, and ensure reliable, future-ready production processes.